ABSTRACT
Thirty-two patients treated on consecutive Southwest Oncology Group (SWOG) protocols for malignant lymphoma were subsequently diagnosed as having lymphoblastic lymphoma. Combination chemistry, usually adriamycin-based, produced complete responses (CR) in 17 patients (53%). Median survival was 15 mo. Patients achieving a CR survival significantly longer than patients with partial or no response (p < 0.01). Ten of 24 patients not receiving central nervous system (CNS) prophylaxis developed leptomeningeal lymphoma while none of the seven patients who received prophylactic intrathecal cytosine arabinoside or methotrexate developed CNS lymphoma (p = 0.04). Implications of these results for planning future treatment programs of lymphoblastic lymphoma are discussed.
Subject(s)
Lymphoma/drug therapy , Adolescent , Adult , Aged , Child , Child, Preschool , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Drug Therapy, Combination , Female , Humans , Lymphoma/complications , Lymphoma/mortality , Male , Middle Aged , Nervous System Neoplasms/complications , Prednisone/therapeutic use , Vincristine/therapeutic useABSTRACT
Eight patients with advanced metastatic malignant melanoma were treated with tamoxifen at a dose of 10 mg orally twice a day for a minimum of 4 weeks. There was one complete response of skin disease occurring over a period of 40 weeks. This patient has remained disease-free for 8+ weeks. Two other patients demonstrated a partial but brief (4 weeks) shrinkage of gross subcutaneous disease. Three patients exhibited no response to the drug, but two patients had rapid acceleration of disease between the second and fourth weeks of treatment. Further exploration of the basis for these favorable and adverse responses is being pursued.
